Fadi Haddad, MD, University of Texas MD Anderson Cancer Center, Houston, TX, discusses evidence that continuing treatment to keep patients at MR4 or MR4.5 for at least 5 years leads to 5-year treatment-free remission rates of around 80%, a significantly better outcome than in patients who discontinued treatment earlier. Dr Haddad stresses that after discontinuing treatment, regular monitoring is crucial, though evidence suggests follow-up every 6 to 8 weeks during the first 6 months may be as effective as every 4 weeks.